← All Sinovac Biotech LTD filings

Sinovac Biotech LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
SVA
Sinovac Biotech LTD
20-F: Sinovac Biotech 2025 Annual Report Analysis
Sinovac Biotech reports a net loss of $198.8 million for 2025 amid ongoing governance disputes and market challenges.
NASDAQ
SVA
Sinovac Biotech LTD
20-F: Sinovac Biotech Ltd. Files 20-F Annual Report, Detailing Financial Performance and Ongoing Legal Challenges
Sinovac Biotech Ltd. has filed its 20-F annual report, providing insights into its financial results for the year ended December 31, 2023, and outlining ongoing legal proceedings that could impact the company's future.